CSIMarket
 


Theriva Biologics inc   (TOVX)
Other Ticker:  
 
 

TOVX's Capital Expenditures Growth by Quarter and Year

Theriva Biologics Inc 's Capital Expenditures results by quarter and year




TOVX Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 0.06 0.01 0.00 0.00
III Quarter September 0.14 0.01 0.00 0.00
II Quarter June 0.01 0.00 0.01 0.00
I Quarter March 0.01 0.00 0.01 0.00
FY   0.22 0.02 0.02 0.00



TOVX Capital Expenditures fourth quarter 2022 Y/Y Growth Comment
Theriva Biologics inc achieved in the fourth quarter 2022, above Company average Capital Expenditures surge of 460% year on year, to $ 0.06 millions.

Looking into fourth quarter 2022 results within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Capital Expenditures growth. While Theriva Biologics Inc ' s Capital Expenditures doubling of 460% ranks overall at the positon no. 160 in the fourth quarter 2022.




TOVX Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December 460 % - - -
III Quarter September 1300 % - - -
II Quarter June - - - -
I Quarter March - - - -
FY   980 % 0 % - -

Financial Statements
Theriva Biologics Inc 's fourth quarter 2022 Capital Expenditures $ 0.06 millions TOVX's Income Statement
Theriva Biologics Inc 's fourth quarter 2021 Capital Expenditures $ 0.01 millions Quarterly TOVX's Income Statement
New: More TOVX's historic Capital Expenditures Growth >>


TOVX Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December -60 % 0 % - -
III Quarter September 1300 % - - -
II Quarter June 0 % - 0 % -
I Quarter March 0 % - - -
FY (Year on Year)   980 % 0 % - -




Capital Expenditures fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #40
Overall #160

Capital Expenditures Y/Y Growth Statistics
High Average Low
1700 % 190.88 % -100 %
(Sep 30 2015)   (Mar 31 2022)
Capital Expenditures fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #40
Overall #160
Capital Expenditures Y/Y Growth Statistics
High Average Low
1700 % 190.88 % -100 %
(Sep 30 2015)   (Mar 31 2022)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Theriva Biologics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
15300 % 701 % -100 %
(Sep 30 2016)  


TOVX's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2022 Theriva Biologics Inc disclosed fall in Capital Expenditures from the third quarter by -60% to $ 0.06 millions, from $ 0.14 millions released a quarter before.

Within Major Pharmaceutical Preparations industry 192 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Theriva Biologics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 3153.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #193
Healthcare Sector #533
Overall #3153
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #193
Healthcare Sector #533
Overall #3153
Capital Expenditures Q/Q Growth Statistics
High Average Low
15300 % 701 % -100 %
(Sep 30 2016)  


TOVX's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2022 Theriva Biologics Inc reported fall in Capital Expenditures from the previous quarter by -60% to $ 0.06 millions, from $ 0.14 millions released a quarter before.

Within Major Pharmaceutical Preparations industry 192 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Theriva Biologics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 3153.


Theriva Biologics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.21 $ 0.17 $ 0.04 $ 0.00 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - - -
Year on Year Capital Expenditures Growth Overall Ranking # # # # #
Seqeuential Capital Expenditures Change (TTM) 24.56 % - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # # # # #




Cumulative Capital Expenditures growth Comment
Theriva Biologics Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 460% year on year, to $ 0 millions if the fiscal year would have ended in Dec 31 2023.
Theriva Biologics Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 0% and higher than % growth in Sep 30 2023. And, Theriva Biologics Inc realized the fastest Capital Expenditures growth, in Major Pharmaceutical Preparations industry.
But from the previous reporting period increase was slower at 24.56 % from $0.17 millions reported in twelve months ending a quarter before Bryan I. Lyons continued.
Yet this was evidence of strength, as the typical Q/Q TTM advancement is at 0%.

Theriva Biologics inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 147
S&P 500 # 979
Cumulative Capital Expenditures growth Comment
Theriva Biologics Inc saw improvement in Capital Expenditures growth trend, posting cumulative 12 months Capital Expenditures growth of 460% year on year, to $ 0 millions if the fiscal year would have ended in Dec 31 2023.
Theriva Biologics Inc 's trailing twelve months Capital Expenditures growth was higher than company's average 0% and higher than % growth in Sep 30 2023. And, Theriva Biologics Inc realized the fastest Capital Expenditures growth, in Major Pharmaceutical Preparations industry.
But from the previous reporting period rise was beneth at 24.56 % from $0.17 millions recorded in the period from Sep 30 2023 to Sep 30 2022 Bryan I. Lyons added on.
In spite of, it was validation of convincing trend, as the usual sequential Capital Expenditures growth is at 0%.
The growth was much stronger from the previous reporting period clinched at 24.56 % jump from $0.17 millions in the period from Sep 30 2023 to Sep 30 2022.

Theriva Biologics inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 57
Sector # 147
S&P 500 # 979




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
TOVX's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for TOVX's Competitors
Capital Expenditures Growth for Theriva Biologics Inc 's Suppliers
Capital Expenditures Growth for TOVX's Customers

You may also want to know
TOVX's Annual Growth Rates TOVX's Profitability Ratios TOVX's Asset Turnover Ratio TOVX's Dividend Growth
TOVX's Roe TOVX's Valuation Ratios TOVX's Financial Strength Ratios TOVX's Dividend Payout Ratio
TOVX's Roa TOVX's Inventory Turnover Ratio TOVX's Growth Rates TOVX's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Moonlake Immunotherapeutics720.22%$ 720.224 millions
Exelixis Inc 665.00%$ 664.997 millions
Utah Medical Products Inc626.32%$ 626.316 millions
Alpha Tau Medical Ltd 608.08%$ 608.075 millions
Vericel Corporation596.44%$ 596.444 millions
Generation Bio Co 571.55%$ 571.554 millions
Zynex inc 569.77%$ 569.767 millions
Eyenovia inc 368.64%$ 368.638 millions
Harvard Bioscience Inc351.49%$ 351.489 millions
Urogen Pharma Ltd 330.77%$ 330.769 millions
Hims and Hers Health Inc 328.55%$ 328.550 millions
Masimo Corp295.31%$ 295.313 millions
Axonics Inc 290.15%$ 290.149 millions
Immutep Limited261.07%$ 261.067 millions
Vertex Pharmaceuticals Inc245.54%$ 245.536 millions
Prothena Corporation Public Limited Company233.84%$ 233.836 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com